Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.



Published on

Presentation from OIS@ASCRS 2016
Chris Calcaterra, Chief Commercial Officer

Video Presentation:

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this


  1. 1. © 2016 Glaukos Corporation GLAUKOS: TAKING A MIGS COMPANY PUBLIC Chris Calcaterra, Chief Commercial Officer OIS@ASCRS -- May 5, 2016 1
  3. 3. © 2016 Glaukos Corporation • Completed initial public offering on June 25, 2015 • Shares currently trade on New York Stock Exchange under ticker symbol GKOS 3 NYSE: GKOS
  4. 4. © 2016 Glaukos Corporation 4 The Lead Up • Founded, built and validated MIGS category over a 15+ year period • Selected bankers and other key advisors • Worked closely with advisors to prepare offering documents that described strategy, growth prospects, strengths and risks • Continually evaluated market conditions to identify optimal IPO timing • Prepared for more rigorous financial reporting, ongoing public disclosure and compliance with securities laws and regulations • Expanded board and established new management functions • Prepared the organization for life as a public company • Required more than a year of intense preparation, while continuing to run/grow the business
  5. 5. © 2016 Glaukos Corporation 5 • Met with approx. 140 investors to answer questions and explain strategy, potential, competitive strengths and success factors • Covered 9 cities in 7 days • Strong institutional investor interest: – First-mover advantage; MIGS pioneer – Novel technology platform that addresses true unmet need – Demonstrated track record of operational execution and financial performance – Deep, late-stage product pipeline The Roadshow
  6. 6. © 2016 Glaukos Corporation 6 Day One • Sold 6.9 million newly issued shares • Priced at $18, $3 above initial pricing range • Shares rose 70% on first trading day • Raised $113.6 million in net proceeds
  7. 7. © 2016 Glaukos Corporation 7 Wall Street Views on MIGS Strong Support For Glaukos Novel Strategy: iStent® + Cataract Surgery “ The cataract + MIGS procedure takes a patient who is already having eye surgery and adds in a layer of clinical efficacy at essentially no additional risk, no additional cost to the patient, and no additional inconvenience … Given the strong incentives supporting MIGS adoption, we see significant runway for rapid market growth… “
  8. 8. © 2016 Glaukos Corporation 8 Wall Street Views on MIGS Wide Recognition Of Robust Glaukos And iStent® Growth “We came away from this year’s AAO with a belief that MIGS will continue to represent a rapidly growing market … A theme we heard consistently was that the introduction of iStent has allowed physicians to have more options in treating patients and has a clear place in the treatment paradigm. “
  9. 9. © 2016 Glaukos Corporation 9 Wall Street Views on MIGS “MIGS is hot. The MIGS space has seen two acquisitions in the last six months… “ A View That Glaukos’s Success Has Attracted Followers Into The MIGS Space
  10. 10. © 2016 Glaukos Corporation 1 0 Taking a MIGS Company Public • Providing higher public profile and awareness of the MIGS space • Helping to establish market valuations for MIGS technology and opportunity • Providing capital to invest in continuing development of burgeoning MIGS market/treatment class
  11. 11. © 2016 Glaukos Corporation 1 1 NYSE TRADERS AWAIT THE OPEN OF GKOS STOCK: JUNE 25, 2015 MIGS GOES TO WALL STREET